Navigation Links
NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD

NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD -- NESS ZIONA, Israel, November 9, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD


NESS ZIONA, Israel, November 9, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today that patient enrollment has begun in a Phase 2a clinical study of ND0801, a new product for the treatment of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD) in adults. ND0801, based on a new, proprietary combination with nicotinic actions, is being developed as a dermal patch and will be evaluated for the treatment of cognitive impairment in several disorders including Alzheimer's disease, schizophrenia and advanced Parkinson's disease, among others.

Nicotinic brain circuitry has previously been shown to be involved in a variety of neurological diseases and disorders and, consequently, nicotinic receptors are the target of several agonist drugs under development. Nicotine, however, has had limited potential as a drug because its repeated use downregulates the actions of the nicotinic receptors. Based on pre-clinical studies, ND0801 is believed to work by preventing the desensitization of nicotinic receptors (contributing to nicotine addiction) that otherwise occurs as a result of repeat nicotine applications. The company hopes that, should it overcome the desensitization of nicotine effects, ND0801 may be beneficial in the treatment of cognitive and other central nervous system dysfunctions.

This Phase 2a study, conducted at two centers in Israel, is planned to enroll 45 ADD/ADHD patients. The trial will examine the safety, tolerability and optimal therapeutic dose of ND0801, and will evaluate the cognitive improvement in these subjects following treatment with ND0801, using standard cognition scale tests.

"The start of this clinical study with ND0801 is a major milestone for NeuroDerm. It marks the entry into clinical development of the company's second, innovative product, for the treatment of cognitive impairment," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "Nicotine is believed to have great potential for the treatment of many diseases. We hope that ND0801 might become the first patch to overcome the desensitization of nicotinic receptors, thereby offering an exciting new treatment option in CNS diseases."

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapeutic dermal patches for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations and/or combinations of well established drugs to achieve a new clinical effect or improved clinical benefit. The company's clinical stage products include ND0611, a skin patch for the treatment of Parkinson's disease and ND0801, for the treatment of cognitive dysfunctions in ADD/ADHD and other CNS diseases. Other products for the treatment of various CNS diseases are in different stages of development. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact: Oded S. Lieberman, PhD MBA, Chairman & CEO Tel.: +972-8-946 2729; Cell: +1-617-517 6077

SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
2. American Regent Initiates Voluntary Recall of Magnesium Sulfate Injection, USP 50% (25 grams/50 mL), 50mL Single Dose Vial Lot # 0491
3. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
4. Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
5. Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinsons Disease
6. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
7. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
8. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
9. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
10. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
11. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015  Strengthening its leadership in ... AEX: PHIA) today announced IntelliSpace Portal 8.0 , ... and visualization platform that helps radiologists detect, diagnose and ... 2015 Radiological Society of North America Annual Meeting (RSNA) ... Portal 8.0 helps address the changing demands in radiology ...
(Date:11/29/2015)... 29, 2015   Royal Philips  (NYSE: PHG, AEX: ... at the 2015 Radiological Society of North America Annual ... Place in Chicago . Visitors to ... company,s broad portfolio of integrated Diagnostic Imaging, Clinical Informatics, ... clinical performance, improve workflow and create a superior patient ...
(Date:11/29/2015)... Germany , Nov. 29, 2015  At ... invites attendees to experience the most complete mobile C-arm ... on display is Ziehm Vision RFD 3D, the world,s ... 16 cm edge length per scan volume. In addition, ... first fully motorized mobile C-arm in four axes which ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ... the American Institute of Ultrasound in Medicine! , AIUM ultrasound practice accreditation ... they meet or exceed nationally recognized standards in the performance and interpretation ...
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... "I struggled ... Things that as a Mother and Wife would love to do, I missed. We ... I just happened to call Dr. Zaidan first. They have changed my life drastically. ...
(Date:11/29/2015)... ... ... Cyber Monday deal is a deep 40% or more discount on every item on both ... skin care lover in your circle. Each Christmas, Sublime Beauty offers a special ... are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like Skin Brushes, natural Body ...
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... NewsWatch featured ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... be a reality in the future. , It’s the future because flying cars are ...
(Date:11/29/2015)... Ca (PRWEB) , ... November 29, 2015 , ... Khanna ... American Board of Ophthalmology on November 25th 2015. Peer Certification by the ... field of his specialty. Certification in Ophthalmology is first obtained after the completion of ...
Breaking Medicine News(10 mins):